Program
Potassium Chloride
Also written as “Custodiol”, “HalfLytely” and “PLENVU®”.
Its studies are mostly in Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 3 companies.
Drug pagePotassium Chloride: every studyAll 43 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. F. Köhler Chemieits history only | 41 open or running | phase 3since Feb 14, 2014 | Sep 29, 2011 | Jan 2027phase 2 · NCT06032195 |
| Sebela Pharmaceuticalsits history only | 30 open or running | phase 4since Sep 9, 2005 | Sep 9, 2005 | none ahead |
| Norgine | 11 open or running | phase 3since Oct 16, 2025 | Oct 16, 2025 | Jan 6, 2027phase 3 · NCT07218523 |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Norgine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2025First study: phase 3 study in Bowel Cleansing Prior to Clinical ProceduresFirst studyNCT07218523 · 212 planned · Belgium, Croatia, Germany and more
Ahead
- Jan 6, 2027Primary completion: phase 3 study in Bowel Cleansing Prior to Clinical ProceduresNCT07218523
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Norgine leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07218523Bowel Cleansing Prior to Clinical Procedures · Belgium, Croatia, Germany and more | 3 | Recruiting | Jan 6, 2027 | 212 |
How it is read
Names in the registry
- “Custodiol”, 4 entries
- “HalfLytely”, 3 entries
- “PLENVU®”, 1 entry
Conditions, from the studies’ own filings
- Aortic Valve Disease, 1 study
- Heart Failure, 1 study
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.